OF-1 | DNA/RNA Synthesis inhibitor | Highly Cited | In Stock

Jump to

Quality Control

Batch: S768101 DMSO]76 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.19%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.19

Related Targets	HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK
Other DNA/RNA Synthesis Inhibitors	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone

Solubility

In vitro
Batch:

DMSO : 76 mg/mL (172.6 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 30%PEG300 2 5%Tween80 3 60%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (6.81mM)	Taking the 1 mL working solution as an example, add 50 μL of 60 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 600 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	440.31	Formula	C₁₇H₁₈BrN₃O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	919973-83-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1=C(C=CC(=C1)Br)S(=O)(=O)NC2=CC3=C(C=C2OC)N(C(=O)N3C)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	BRPF1B 100 nM(Kd) BRPF2 500 nM(Kd)
In vitro	As a chemical probe for BRPF bromodomains, OF-1 increases thermal stability in the cellular thermal shift assay of full length BRPF1B at 1 μM and also demonstrates accelerated FRAP recovery at 5 μM in the BRPF2 FRAP assay. In addition, this compound shows modest general cytotoxicity.
References	[1] http://www.thesgc.org/chemical-probes/OF-1

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-09)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07329569	NOT_YET_RECRUITING	Chemical Burns; Ocular Burns	Fondation Ophtalmologique Adolphe de Rothschild	2026-03	PHASE2
NCT04580368	RECRUITING	Cystic Fibrosis	Children's Hospital Medical Center, Cincinnati	2021-05-01
NCT07321691	NOT_YET_RECRUITING	Deafness	University Hospital, Toulouse	2026-09
NCT07668856	RECRUITING	Refractory Epilepsy in Children; Refractory Epilepsy; Epilepsy	UMC Utrecht	2025-02-06	PHASE3
NCT07497568	RECRUITING	Dental Implant; Stability	University of Baghdad	2025-11-01
NCT01687127	NOT_YET_RECRUITING	One-carbon Metabolism in Healthy Individuals	University of British Columbia	2024-01-01

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

OF-1 DNA/RNA Synthesis inhibitor

Chemical Structure

Molecular Weight: 440.31